Cargando…

Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease

BACKGROUND: The use of national medico-administrative databases for epidemiological studies has increased in the last decades. In France, the Healthcare Expenditures and Conditions Mapping (HECM) algorithm has been developed to analyse and monitor the morbidity and economic burden of 58 diseases. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanorio-Vega, Isabella, Constantinou, Panayotis, Hami, Assia, Cellarier, Eric, Rachas, Antoine, Tuppin, Philippe, Couchoud, Cécile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594771/
https://www.ncbi.nlm.nih.gov/pubmed/37872574
http://dx.doi.org/10.1186/s12913-023-10145-y
_version_ 1785124720424779776
author Vanorio-Vega, Isabella
Constantinou, Panayotis
Hami, Assia
Cellarier, Eric
Rachas, Antoine
Tuppin, Philippe
Couchoud, Cécile
author_facet Vanorio-Vega, Isabella
Constantinou, Panayotis
Hami, Assia
Cellarier, Eric
Rachas, Antoine
Tuppin, Philippe
Couchoud, Cécile
author_sort Vanorio-Vega, Isabella
collection PubMed
description BACKGROUND: The use of national medico-administrative databases for epidemiological studies has increased in the last decades. In France, the Healthcare Expenditures and Conditions Mapping (HECM) algorithm has been developed to analyse and monitor the morbidity and economic burden of 58 diseases. We aimed to assess the performance of the HECM in identifying different conditions in patients with end-stage kidney disease (ESKD) using data from the REIN registry (the French National Registry for patients with ESKD). METHODS: We included all patients over 18 years of age who started renal replacement therapy in France in 2018. Five conditions with a similar definition in both databases were included (ESKD, diabetes, human immunodeficiency virus [HIV], coronary insufficiency, and cancer). The performance of each SNDS algorithm was assessed using sensitivity, specificity, positive predictive values (PPVs), negative predictive values (NPVs), and Cohen’s kappa coefficient. RESULTS: In total 5,971 patients were included. Among them, 81% were identified as having ESKD in both databases. Diabetes was the condition with the best performance, with a sensitivity, specificity, PPV, NPV, and Kappa coefficient all over 80%. Cancer had the lowest level of agreement with a Kappa coefficient of 51% and a high specificity and high NPV (94% and 95%). The conditions for which the definition in the HECM included disease-specific medications performed better in our study. CONCLUSION: The HECM showed good to very good concordance with the REIN database information overall, with the exception of cancer. Further validation of the HECM tool in other populations should be performed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-10145-y.
format Online
Article
Text
id pubmed-10594771
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105947712023-10-25 Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease Vanorio-Vega, Isabella Constantinou, Panayotis Hami, Assia Cellarier, Eric Rachas, Antoine Tuppin, Philippe Couchoud, Cécile BMC Health Serv Res Research BACKGROUND: The use of national medico-administrative databases for epidemiological studies has increased in the last decades. In France, the Healthcare Expenditures and Conditions Mapping (HECM) algorithm has been developed to analyse and monitor the morbidity and economic burden of 58 diseases. We aimed to assess the performance of the HECM in identifying different conditions in patients with end-stage kidney disease (ESKD) using data from the REIN registry (the French National Registry for patients with ESKD). METHODS: We included all patients over 18 years of age who started renal replacement therapy in France in 2018. Five conditions with a similar definition in both databases were included (ESKD, diabetes, human immunodeficiency virus [HIV], coronary insufficiency, and cancer). The performance of each SNDS algorithm was assessed using sensitivity, specificity, positive predictive values (PPVs), negative predictive values (NPVs), and Cohen’s kappa coefficient. RESULTS: In total 5,971 patients were included. Among them, 81% were identified as having ESKD in both databases. Diabetes was the condition with the best performance, with a sensitivity, specificity, PPV, NPV, and Kappa coefficient all over 80%. Cancer had the lowest level of agreement with a Kappa coefficient of 51% and a high specificity and high NPV (94% and 95%). The conditions for which the definition in the HECM included disease-specific medications performed better in our study. CONCLUSION: The HECM showed good to very good concordance with the REIN database information overall, with the exception of cancer. Further validation of the HECM tool in other populations should be performed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-10145-y. BioMed Central 2023-10-24 /pmc/articles/PMC10594771/ /pubmed/37872574 http://dx.doi.org/10.1186/s12913-023-10145-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Vanorio-Vega, Isabella
Constantinou, Panayotis
Hami, Assia
Cellarier, Eric
Rachas, Antoine
Tuppin, Philippe
Couchoud, Cécile
Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease
title Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease
title_full Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease
title_fullStr Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease
title_full_unstemmed Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease
title_short Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease
title_sort cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594771/
https://www.ncbi.nlm.nih.gov/pubmed/37872574
http://dx.doi.org/10.1186/s12913-023-10145-y
work_keys_str_mv AT vanoriovegaisabella crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease
AT constantinoupanayotis crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease
AT hamiassia crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease
AT cellariereric crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease
AT rachasantoine crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease
AT tuppinphilippe crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease
AT couchoudcecile crossvalidationofcomorbidityitemsintwonationaldatabasesinasampleofpatientswithendstagekidneydisease